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Osteomyelitis is a debilitating bone infection often caused by the bacterial pathogen Staphylococcus aureus.
In this issue, Cassat et al. (2013) develop a high-resolutionmicrocomputed tomography (microCT) method to
visualize bone remodeling duringS. aureus infection and discover that themetalloprotease aureolysin plays a
critical role in modulating osteomyelitis pathogenesis.Osteomyelitis is a bacterial infection of the
bone or bone marrow that affects an
alarming number of patients that are
admitted to hospitals (Lew and Waldvo-
gel, 2004). Staphylococcus aureus is a
prominent bacterial pathogen and the
most frequent isolated causal agent of
infection-induced osteomyelitis (Hatzen-
buehler and Pulling, 2011). Treatment of
osteomyelitis infections is challenging
due a variety of factors including the
poor bioavailability of antibiotics in bone
tissue, rising antibiotic resistance in bac-
terial pathogens, and the biofilm-like
properties of the infection. In many cases,
physicians are left with surgical debride-
ment as the only option to remove the
invading bacteria and achieve a sterile
site. When an infected prosthetic joint is
involved, removal and replacement of
the joint is often required (Zimmerli et al.,
2004). Due to these challenges, osteomy-
elitis is devastating formany patients, with
painful long-term consequences and
limited treatment options.
Improving the clinical outcomes of
osteomyelitis infections would be a sig-
nificant medical advance. Our current
limited knowledge of disease progression
and the availability of technologies to
monitor these events is an unmet need
that has hampered ongoing studies. In
this issue of Cell Host & Microbe, Cassat
et al. (2013) address these challenges by
developing and utilizing a novel three-
dimensional imaging modality called
high-resolution microcomputed tomogra-
phy (microCT) that can visualize and
quantify infectious damage to the bone.
To perform microCT, a new model of
murine osteomyelitis was developed and
confirmed using a community-acquired
methicillin-resistant S. aureus isolate ofthe USA300 type, an emerging cause of
musculoskeletal infections (Kourbatova
et al., 2005). In the murine model, a sterile
1 mm unicortical bone defect is created,
serving as an S. aureus inoculation point
to establish osteomyelitis. To monitor dis-
ease progression, microCT is performed
to visualize cortical bone destruction and
new bone formation, and computational
algorithms translate these changes into
a three-dimensional image. The end result
is a visual reconstruction that captures a
striking snapshot of bone remodeling
as a result of S. aureus infection (see
Figure 1). The developed imaging soft-
ware provides informative volume outputs
of bone loss and new bone growth that
serve an important role in quantifying
osteomyelitis-related damage. To verify
the microCT findings, the authors (Cassat
et al., 2013) performed histopathology on
the murine model. Thus, the methods
developed in this paper make it possible
to monitor and quantify osteomyelitis dis-
ease for the first time using a powerful
new imaging platform.
To gain insight into S. aureus mech-
anisms of osteomyelitis pathogenesis,
Cassat et al. (2013) employed themicroCT
imaging technology on USA300 and
isogenic mutants in previously described
key pathogenesis regulators. Due to
the limited knowledge of contributing
factors to this disease, a S. aureus strain
lacking two global virulence regulators
(Agr and Sae systems) was tested in the
murinemodel. The doublemutant showed
significantly less cortical bone destruction
and reduced new bone formation, indi-
cating that secreted virulence factors
were likely critical contributors to disease.
To focus the subsequent studies, single
mutants were tested, and a sae mutantCell Host & Microbecaused less bone destruction and a signif-
icant decrease in S. aureus burden as
compared to an agr mutant. To confirm
these observations and delve deeper
into the mechanism, in vitro cell culture
assays of osteoblasts indicated that,
indeed, the sae mutant displayed a less-
virulent phenotype. Further, proteomic
approaches were used to investigate
exoproteome changes and uncovered
49 proteins downregulated and 31 pro-
teins upregulated in the saemutant. Inter-
estingly, the bacterial metalloprotease
aureolysin was most enriched in abun-
dance, a fact supported by previous regu-
latory studies on saemutants.
Building on previous reports on how
aureolysin modulates pathogenic capac-
ity (Zielinska et al., 2011), Cassat et al.
(2013) hypothesized that aureolysin func-
tions as the primary switch responsible for
inducing bone remodeling during infec-
tion by tailoring the S. aureus-secreted
virulence factor arsenal. Aureolysin is a
calcium- and zinc-dependent metalloen-
zyme and one of the four major extracel-
lular proteases secreted by S. aureus
strains. The enzyme self activates upon
secretion, preferentially cleaves on the
amino-terminal side of branched-chain
amino acids, and serves as the start-
ing point of the proteolytic activation
cascade. The authors (Cassat et al.,
2013) compared exoproteome pools to
identify proteins that were aureolysin
labile. One group of proteins that stood
out were the alpha-type phenol-soluble
modulins (PSMs), which is a collection of
four low-molecular-weight peptide toxins
with known functions in neutrophil killing
and infection. Assessment of a S. aureus
strain lacking PSMa1–PSMa4 indicated
that this mutant had pronounced defects13, June 12, 2013 ª2013 Elsevier Inc. 629
Figure 1. Imaging S. aureus-Induced Pathologic Bone Remodeling during Osteomyelitis
S. aureus triggers profound alterations in bone remodeling during osteomyelitis (left image). Cassat et al.
(2013) created imaging analysis algorithms to precisely quantify pathologic new bone formation (green)
and cortical bone destruction (yellow), enabling comparison of the destructive capacity of different
staphylococcal strains. Image provided courtesy of Dr. James Cassat (Vanderbilt University School of
Medicine).
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Previewsin osteoblast killing as well as significant
attenuation in bone destruction and new
bone growth in the murine model.
Follow-up studies relying on exogenous
peptide addition demonstrated that
chemically synthesized PSMa2 was the
most cytotoxic to osteoblasts, whereas
PSMa4 was relatively nontoxic. Pretreat-
ment of PSMa peptides with aureolysin
greatly diminished their cytotoxic proper-
ties to osteoblasts, supporting previous
studies that these peptides serve as
aureolysin substrates (Gonzalez et al.,
2012). Thus, by controlling the extra-
cellular concentration of one enzyme,
S. aureus is able to modulate the potency
of its own secreted proteome and dictate
the course of osteomyelitis and poten-
tially other infections. While the authors
focused on the contribution of PSMa
peptides to osteomyelitis, proteomic
analysis demonstrated that numerous
other factors are influenced by aureolysin
levels, indicating that the exoproteome is
a dynamic entity and aureolysin functions
as a rheostat to modulate pathogenic
capacity.
Going beyond this study, the develop-
ment of the new microCT imaging plat-
form has the potential to assess osteo-
myelitis with other pathogens or related
bone infections. A number of other bacte-630 Cell Host & Microbe 13, June 12, 2013 ªrial pathogens cause osteomyelitis,
including Staphylococcus epidermidis,
Streptococcus pyogenes, Acinetobacter
baumannii, Pseudomonas aeruginosa,
and Escherichia coli, and one could easily
imagine applying this murine model and
microCT approach to monitoring disease
progression and follow-up mechanistic
analysis with any of these pathogens.
Additionally, as the authors state (Cassat
et al., 2013), the work could serve as
means to test chemo- or immunothera-
peutic approaches to osteomyelitis treat-
ments, taking advantage of the imaging
platform as a means of monitoring
and quantifying bone damage and re-
growth. There is also potential to apply
the murine model and microCT approach
to other related types of bone infections.
S. aureus is a leading cause of prosthetic
joint infections (Kourbatova et al., 2005,
Zimmerli et al., 2004), and the number of
patients getting joint replacements is
increasing. Infection rates following the
initial replacement are usually low, only
1%–2%, but increase substantially in
revision surgery (Lentino, 2003). When
an infection occurs, it can be a devas-
tating complication with high morbidity
and substantial financial burden. Extend-
ing development of the microCT platform,
it may be possible to assess disease2013 Elsevier Inc.progression in the presence of the im-
planted materials, allowing additional
mechanisms of pathogenesis to be deci-
phered in this context. Going further,
there is special consideration in orthope-
dic surgery for the high rate of infections
in osteoarticular allograft reconstructions.
These reconstructions permit reesta-
blishment of skeletal continuity and func-
tion after a wide resection of bone
tumor, and allografts are increasingly
used in the salvage of difficult bone stock
deficiencies following failed total joint re-
placements (Muscolo et al., 2005). How-
ever, allograft infection is a disastrous
complication, as it may lead to limb ampu-
tation (Mankin et al., 2005), and again
S. aureus is one of the most common
causes. A better understanding of the
mechanisms underlying these infections
through further development of the mu-
rine model and microCT platform could
greatly improve the outcomes of surgical
reconstructions.
In recent years, many exciting ad-
vances in infection imaging have been
pioneered by researchers that may even-
tually aid a physician’s assessment
and treatment of certain diseases. The
microCT imaging modality developed in
this work is another impressive example
that can be added to the expanding
toolbox of approaches for monitoring
disease course. Further development
and translation of this technology has
great potential to improve the disease
prognosis for osteomyelitis patients by
both facilitating the ability to track
infection progression and aiding in the
discovery and testing of innovative thera-
peutic interventions. Presently, this tech-
nology can be applied to enhance our
knowledge of S. aureus mechanisms
causing osteomyelitis and potentially
extend to other bacterial pathogens as
well. With the knowledge gained from
the imaging of this murine model, thera-
pies that limit osteomyelitis-dependent
bone destruction and enhance antimi-
crobial efficacy could eventually lead to
improved patient outcomes for this
devastating disease.REFERENCES
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